COVID-19's hidden toll on diabetic organs revealed
NCT ID NCT04805970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at organ changes in people recovering from COVID-19, comparing those with and without type 2 diabetes. Researchers will use scans to measure organ size and volume. The goal is to learn more about how COVID-19 affects the body long-term in diabetic patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how COVID-19 affects organs in people with diabetes, potentially guiding future care.
- What could go wrong
- This is a small observational study with only 35 participants, so findings may not apply to everyone. It does not test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
35 people
The number who actually took part.
- Started
-
Mar 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who were initially hospitalized with laboratory-confirmed SARS-CoV-2 infection \[COVID-19 disease\], who are no-longer considered infectious by approved bioassay
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Diagnosis of T2D according to American Diabetes Association (ADA) criteria. 4. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments. For participant without Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments. Exclusion Criteria: 1. Symptoms of active respiratory viral infection: 1. high temperature (over 37.8°C/100.4°F) 2. cough (consistent for over an hour; 3 or more episodes in 24 hours) 2. Any history of Type I diabetes 3. The participant may not enter the study with any known contraindication to magnetic resonance imaging including 1. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection 2. Metal implants (pacemaker, aneurysm clips) based on Investigator's judgment at Screening 3. Unable to participate in MRI assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening 4. Unable to tolerate MRI imaging or claustrophobia 4. Any condition, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Translational Research Institute
Orlando, Florida, 32804, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Heartbeat test aims to catch hidden nerve damage in diabetes
- Can Home-Delivered meals help control diabetes?
- Can mindfulness and yoga rewire diabetes habits?
- New pill takes aim at blood sugar in diabetes
- Home c-peptide tests could reveal hidden insulin production in diabetes